Cargando…
盐酸恩沙替尼胶囊的药理与临床评价
Lung cancer is one of the most common malignancies with the highest incidence rate and mortality rate worldwide, and non-small cell lung cancer (NSCLC) accounts for about 85%. Only 5% NSCLC patients are anaplastic lymphoma kinase (ALK) rearrangement positive NSCLC, but the prognosis of these patient...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467989/ https://www.ncbi.nlm.nih.gov/pubmed/32838492 http://dx.doi.org/10.3779/j.issn.1009-3419.2020.102.34 |
Ejemplares similares
-
克里唑替尼治疗晚期非小细胞肺癌的临床研究进展
Publicado: (2013) -
盐酸埃克替尼一线治疗晚期肺腺癌的临床疗效观察
Publicado: (2013) -
加速康复外科评价指标:病人报告结局在胸外科的临床应用现状与进展
Publicado: (2019) -
盐酸埃克替尼治疗晚期复发非小细胞肺癌的临床疗效
Publicado: (2013) -
BCR-ABL突变检测指导下的达沙替尼治疗伊马替尼耐药的慢性髓性白血病疗效分析
Publicado: (2016)